Two Sigma Advisers
RYTM icon

Two Sigma Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History

Two Sigma Advisers’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,900
Closed -$310K – 1746
2025
Q4 		$310K Sell
2,900
-400
-12% -$42.4K ﹤0.01% 1970
2025
Q3 		$333K Sell
3,300
-6,400
-66% -$594K ﹤0.01% 1928
2025
Q2 		$613K Sell
9,700
-2,400
-20% -$147K ﹤0.01% 1657
2025
Q1 		$641K Sell
12,100
-1,000
-8% -$55.5K ﹤0.01% 1672
2024
Q4 		$733K Buy
13,100
+300
+2% +$16.6K ﹤0.01% 1612
2024
Q3 		$671K Buy
12,800
+3,900
+44% +$187K ﹤0.01% 1589
2024
Q2 		$365K Buy
+8,900
New +$355K ﹤0.01% 1998
2021
Q2 		– Sell
-47,800
Closed -$1.02M – 2658
2021
Q1 		$1.02M Buy
+47,800
New +$1.39M ﹤0.01% 1642

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Two Sigma Advisers's RYTM Position: Q1 2026 in Review

Two Sigma Advisers sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 2,900 shares — an estimated $310K sold.

Two Sigma Advisers first reported a position in RYTM in Q1 2021 and held it in 8 quarters. The position peaked at $1.02M in Q1 2021. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Two Sigma Advisers reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 2,900 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $310K.
  • Two Sigma Advisers first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Two Sigma Advisers's Rhythm Pharmaceuticals position peaked at $1.02M in Q1 2021.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.